Has Stephen Fehnel received payments from drug or device companies?

Yes. Drug and device makers reported $4,840 in general payments to Stephen Fehnel across 102 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Stephen Fehnel did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Stephen Fehnel come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Stephen Fehnel

Gynecology · West Reading, PANPI 1790759157

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (57.4%), travel and lodging and education — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Axonics, Inc. at 57.9% of the total. Reporting peaked in 2022 at $2,223 and has fallen 82.2% since, to $395 in 2023.

$4,840in general payments, 2019–2025

Across 102 payments — averaging $47.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Axonics, Inc.$3K
Novo Nordisk$802
AbbVie$478
Astellas Pharma US Inc$235
Pfizer$151
Amgen$142
plus $229 from 8 others

$429,889in research payments, 2019–2025

Across 121 payments — averaging $3552.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novo Nordisk AS$303K
Bayer$69K
AbbVie$37K
GSK$17K
BD$3K

What the payments were for

Travel & lodging$1,88739%
Food & beverage$2,77957%
Education$1353%
Other$391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Axonics, Inc.	29	$2,804
Novo Nordisk	23	$802
AbbVie	20	$478
Astellas Pharma US Inc	7	$235
Pfizer	9	$151
Amgen	2	$142
Avion Pharmaceuticals	3	$43
Applied Medical Resources Corporation	1	$42
Baxter Healthcare	1	$39
Mayne Pharma Commercial LLC	2	$32
Hologic Sales And Service, LLC	2	$28
KARL Storz Endoscopy-america	1	$16
Radius Health, Inc.	1	$16
Minerva Surgical, Inc	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,840 in reported general payments places this provider in the 85th percentile of 98 gynecology providers in Pennsylvania.

See all gynecology providers in Pennsylvania →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MyrbetriqMirabegron	16	$19,850
Estradiol	24	$1,506

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Astellas Pharma US IncMyrbetriq	$235	$19,85016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 98 gynecology providers in Pennsylvania.